Castle Biosciences, Inc.
CSTL
$24.06
$0.502.12%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 117.50% | -369.53% | 322.65% | -74.56% | 452.01% |
| Total Depreciation and Amortization | -88.53% | 416.02% | 62.89% | 5.76% | 0.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -58.06% | 48.48% | -58.07% | 70.63% | -11.99% |
| Change in Net Operating Assets | 141.75% | -1,127.79% | 155.54% | -59.41% | 110.17% |
| Cash from Operations | 444.95% | -124.77% | 4.40% | -2.75% | 451.10% |
| Capital Expenditure | -95.42% | 37.36% | -18.64% | -21.97% | 42.86% |
| Sale of Property, Plant, and Equipment | 33.33% | 28.57% | 75.00% | 100.00% | -60.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 97.73% | -232.78% | 258.41% | 48.02% | -53.40% |
| Cash from Investing | -26.51% | -488.75% | 139.02% | 30.95% | -8.71% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -19.23% | 0.00% | -8.33% | -118.18% | 69.44% |
| Issuance of Common Stock | -46.26% | -3.14% | -52.69% | 222.75% | -42.11% |
| Repurchase of Common Stock | 76.58% | 60.57% | -392.97% | -110.41% | -29.75% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 106.50% | 71.16% | -742.60% | 1,895.24% | -99.61% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 75.16% | -221.29% | 163.66% | 257.87% | 116.51% |